Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
301130
Company Profile
Business description
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd is mainly engaged in the research, development, production, and sales of chemical APIs and preparations. It is focused on the development and manufacturing of iron supplement preparations, circulatory disorder treatment drugs, anti-psychotic drugs, and APIs. The company's product portfolio comprises Compound Ferrous Sulfate Folic Acid Tablets, Risperidone Orally Disintegrating Tablets, Escitalopram Oxalate Tablets, Daphne Capsules, Zoledronic Acid for Injection, etc., and various APIs.
Contact
No. 777, Xidian Street
Panshi Economic Development Zone
Jilin Province
Panshi132300
CHNT: +86 43265888277
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
320
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,111.10 | 82.30 | 0.91% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 24,910.63 | 8.10 | 0.03% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 40,794.86 | 245.32 | 0.60% |
| NZX 50 Index | 12,880.16 | 3.12 | 0.02% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,843.70 | 73.30 | 0.84% |
| SSE Composite Index | 3,633.99 | 16.40 | 0.45% |